Development of an early mortality risk prediction model for pediatric hemophagocytic lymphohistiocytosis

Author:

Tang Zhexuan,Li Xun,Yan Haipeng,Luo Ting,Xie Longlong,Yang Yufan,Tang Minghui,Jiang Xuedan,Huang Jiaotian,Zhang Xinping,Xiao Zhenghui,Lu Xiulan1ORCID

Affiliation:

1. Hunan Children's Hospital

Abstract

Abstract Background Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening disease with rapid progressing and high mortality, which is more commonly seen in children. Objective Our goal was to develop a novel model for predicting early mortality risk in pediatric HLH patients using readily accessible parameters and build a nomogram. Methods We conducted a retrospective analysis of 170 pediatric HLH patients diagnosed at Hunan Children's Hospital between March 1, 2017, and March 1, 2022. These patients were split into a training cohort and a validation cohort. Early mortality was defined as 28-day mortality post-diagnosis. A prediction model with nomogram was developed using binary logistic regression analysis in the training cohort. The model underwent internal and external validation using the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA). Results The final prediction model included 11 predictor variables: glutamic-pyruvic transaminase, albumin, globulin, myohemoglobin, creatine kinase, serum potassium, procalcitonin, serum ferritin, the interval between onset and diagnosis, and the interval between admission and diagnosis. The 28-day mortality prediction AUC was 0.957 in the training cohort and 0.929 in the validation cohort. Utilizing the 28-day mortality prediction for estimating 7-day and 14-day mortality, the AUC values were 0.930 and 0.938, respectively. The calibration plot revealed an adequate fit with 1000 bootstrap resampling and the DCA exhibited great net benefit. Conclusion The study constructed a novel prediction model with nomogram in pediatric HLH, which could contribute to rapid assessment early mortality risk after diagnosis with readily available parameters, providing clinical support to identify patients with a poor prognosis and enhancing their prognostic outcomes.

Publisher

Research Square Platform LLC

Reference25 articles.

1. Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy;Griffin G;Best Pract Res Clin Rheumatol,2020

2. Hemophagocytic Lymphohistiocytosis;Al-Samkari H;Annu Rev Pathol,2018

3. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study;Bergsten E;Blood,2017

4. Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood 2020 Apr 16;135(16):1332–43.

5. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO);Jordan MB;Pediatr Blood Cancer,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3